ClinicalTrials.gg

Program

zalfermin

Also written as “NNC0194-0499”, “NNC0194-0499/Semaglutide A (40/3.20 mg/mL)” and “NNC0194-0499/Semaglutide A (40/0.33mg/mL)”.

In Novo Nordisk's own words, a long-acting FGF-21 analogue. Its studies are mostly in Non-alcoholic Fatty Liver Disease · Obesity · Diabetes Mellitus, Type 1, led by Novo Nordisk.

Furthest: phase 2, since May 7, 202410 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk101 open or runningphase 2since May 7, 2024Jan 6, 2017none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 6, 2017First study: phase 1 study in Nutrition DisordersFirst studyNCT03015207 · 56 enrolled · United States
  2. Mar 9, 2018Phase 1 study in Nutrition DisordersNCT03479892 · 57 enrolled · United States
  3. Jan 21, 2021Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT04722653 · 42 enrolled · Japan
  4. Feb 5, 20233 phase 1 studies in Non-alcoholic Fatty Liver DiseaseNCT05727644, NCT05742919, NCT05766709
  5. Jun 8, 2023Phase 1 study in Hepatic ImpairmentNCT05917938 · 33 enrolled · Germany, Poland, Slovakia
  6. Dec 14, 2023Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT06188026 · 34 enrolled · Austria
  7. May 7, 2024Phase 2 study in Alcohol-related Liver DiseaseNCT06409130 · 270 enrolled · United States, Australia, Bulgaria and more
  8. Jun 29, 2025Phase 1 study in Diabetes Mellitus, Type 1NCT07087795 · 96 enrolled · Germany

TargetBeta

“a long-acting FGF-21 analogue”company filing, read by Claude · source

Other programs on FGF21

ProgramCompanyFurthest phaseStudies
efimosfermin alfaGlaxoSmithKlinephase 310
pegozafermin89bio-incphase 38
efruxiferminNovo Nordiskphase 36

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07087795Diabetes Mellitus, Type 1 · Germany1Active, not recruitingSep 12, 202696
NCT06409130Alcohol-related Liver Disease · United States, Australia, Bulgaria and more2CompletedNov 21, 2025270
NCT06188026Non-alcoholic Fatty Liver Disease · Austria1CompletedDec 30, 202434
NCT05917938Hepatic Impairment · Germany, Poland, Slovakia1CompletedDec 16, 202433
NCT05766709Non-alcoholic Fatty Liver Disease · Canada1CompletedJan 5, 202453
NCT05742919Non-alcoholic Fatty Liver Disease · China1CompletedJun 13, 202324
NCT05727644Non-alcoholic Fatty Liver Disease · Germany1CompletedNov 10, 202342
NCT04722653Non-alcoholic Fatty Liver Disease · Japan1CompletedApr 27, 202142
NCT03479892Nutrition Disorders · United States1CompletedJun 4, 201957
NCT03015207Nutrition Disorders · United States1CompletedOct 26, 201756

How it is read

Names in the registry

  • “NNC0194-0499”, 11 entries
  • “NNC0194-0499/Semaglutide A (40/3.20 mg/mL)”, 1 entry
  • “NNC0194-0499/Semaglutide A (40/0.33mg/mL)”, 1 entry

Codes read as this program: NNC01940499.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.